Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292222 · ClinicalTrials.gov registry record · NA
Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
A NA study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT05292222 is a NA study that has completed, run by HealthPartners Institute. The registered enrollment target is 15 participants.
The verdict
NCT05292222, a NA study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 6.2 million individuals in the United States, resulting in an annual cost of care of $305 billion. AD is functionally characterized by progressive degeneration of large-scale brain networks (LSBNs), including the default mode network (DMN) presumably from the deposition of amyloid plaques and neurofibrillary tangles. Available FDA-approved medications for AD such as donepezil and memantine offer limited benefit and modest impact on quality of life. In combination with resting state functional MRI (rs-fMRI), transcranial magnetic stimulation (TMS) with intermittent theta burst stimulation (iTBS) offers a non-invasive alternative to pharmacotherapy in persons with AD. We propose a pilot trial using rs-fMRI to target dysfunctional LSBNs in early stage AD.
Interventions
- DEVICE Intermittent theta burst stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-06-17 |
| Est. Completion | 2023-11-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05292222
The ClinicalTrials.gov registry entry for NCT05292222 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intermittent theta burst stimulation is the first listed.
NCT05292222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05292222 about?
NCT05292222 is a clinical study titled "Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease". Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 6.2 million individuals in the United States, resulting in an annual cost of care of $305 billion. AD is functionally characterized by progressive degeneration of large-scale brain networks (LSBNs), including the default...
What is the current status of trial NCT05292222?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-06-17. Estimated completion is 2023-11-07.
What interventions are being tested in trial NCT05292222?
The interventions under investigation include: Intermittent theta burst stimulation (DEVICE).
Who is sponsoring clinical trial NCT05292222?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.